ResourcesVendorsRadiopharmaceuticalsRadiopharmeceuticals Nuclear MedicineBlue Earth Diagnostics26 Mall Road, Suite 206, Burlington, MA, 01803eMail:Website:https://www.blueearthdiagnostics.com.LinkedIn iconLatest from Blue Earth DiagnosticsMolecular ImagingBlue Earth secures $76.5M in financing roundBy AuntMinnie.com staff writersBracco Imaging subsidiary Blue Earth Therapeutics closed on $76.5 million in a series A financing round.October 30, 2024Molecular ImagingBlue Earth Diagnostics highlights results from Spotlight studyBy AuntMinnie.com staff writersBlue Earth Diagnostics, a Bracco company, is highlighting Posluma results from the phase III Spotlight study.July 30, 2024Molecular ImagingBlue Earth Diagnostics taps new CEOBy AuntMinnie.com staff writersBracco subsidiary Blue Earth Diagnostics has appointed a new CEO.July 8, 2024Molecular ImagingBlue Earth, Siemens ink deal for Posluma clinical trialBy AuntMinnie.com staff writersThe agreement enables Siemens to enhance its analytics and AI-based algorithms for prostate cancer image quantification and interpretation.May 9, 2024Nuclear MedicineBlue Earth Diagnostics inks deal with Sinotau PharmaceuticalBy AuntMinnie.com staff writersBlue Earth Diagnostics and Sinotau Pharmaceutical have formed a partnership in China involving Blue Earth's flotufolastat F-18 PET radiotracer.October 17, 2023Radiation Oncology/TherapyBlue Earth touts studies at ASTRO meetingBy AuntMinnie.com staff writersBlue Earth Diagnostics will present studies on its Posluma PET radiotracer at the American Society for Radiation Oncology (ASTRO) annual meeting.September 27, 2023Molecular ImagingNCCN adds Blue Earth's Posluma to its oncology guidelinesBy AuntMinnie.com staff writersThe National Comprehensive Cancer Network (NCCN) has added Blue Earth Diagnostics' Posluma (Flotufolastat F-18) PET radiotracer to its oncology guidelines for imaging prostate cancer.July 24, 2023Nuclear MedicineBlue Earth highlights Posluma study resultsBy AuntMinnie.com staff writersBlue Earth Diagnostics, a Bracco company, is highlighting results from a study that explored the impact of urinary activity on the interpretation of its flotufolastat F-18 injection (Posluma).June 26, 2023Molecular ImagingFDA approves new PET tracer for prostate cancer imagingBy AuntMinnie.com staff writersThe U.S. Food and Drug Administration (FDA) has approved Blue Earth Diagnostics' F-18 rhPSMA-7.3 PET radiotracer for detecting prostate cancer.May 29, 2023Nuclear MedicineBlue Earth touts clinical resultsBy AuntMinnie.com staff writersBlue Earth Diagnostics is highlighting results from a clinical study that has investigated the efficacy of the PET imaging agent F-18 rhPSMA-7.3 for detecting recurrent prostate cancer.April 30, 2023Molecular ImagingBlue Earth highlights results from PET tracer trialBy AuntMinnie.com staff writersBlue Earth Diagnostics is highlighting results from a phase III clinical trial that tested its diagnostic PET imaging radiotracer F-18 rhPSMA-7.3 in newly diagnosed prostate cancer patients.February 16, 2023Molecular ImagingPET tracer shows promise in imaging of brain tumorsBy Will MortonA widely available amino acid PET radiotracer shows promise in helping clinicians distinguish between pseudoprogression and actual tumor progression in patients with brain tumors, according to a study published December 22 in the Journal of Nuclear Medicine.January 3, 2023Molecular ImagingBlue Earth touts PSMA radiotracer studyBy AuntMinnie.com staff writersBlue Earth Diagnostics has released top-line results from its phase III trial evaluating the performance of its prostate-specific membrane antigen (PSMA) radiotracer for imaging in newly diagnosed prostate cancer.December 1, 2022Molecular ImagingBlue Earth to highlight PET study results at ASTROBy AuntMinnie.com staff writersBlue Earth Diagnostics will highlight study results for its experimental PET radiotracer F-18 rhPSMA-7.3 at the American Society for Radiation Oncology (ASTRO) 2022 annual meeting being held October 23 to 26 in San Antonio, TX.October 18, 2022Molecular ImagingSiemens scores access to PET data in deal with Blue EarthBy AuntMinnie.com staff writersSiemens Healthineers has inked a data-sharing deal with Blue Earth Diagnostics for access to anonymized radiohybrid prostate-specific membrane antigen (PSMA) F-18 rhPSMA-7.3 clinical data and images.October 17, 2022
